Ticos Omega Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.10 M
as on 29-06-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2022)
- Profit 43.47%
(FY 2022)
- Ebitda 51.88%
(FY 2022)
- Net Worth -87.45%
(FY 2022)
- Total Assets 474.39%
(FY 2022)
About Ticos Omega Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mitesh Raval, Hiren Raval, Jayesh Raval, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24100GJ2020PTC112474
- Company No.
112474
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2020
- Date of AGM
15 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ticos Omega Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaynesh Patel  | Director | 03-Feb-2020 | Current |
| Mitesh Raval | Director | 03-Feb-2020 | Current |
| Hiren Raval | Director | 03-Feb-2020 | Current |
| Jayesh Raval | Director | 03-Feb-2020 | Current |
| Payal Patel | Director | 03-Feb-2020 | Current |
Financial Performance of Ticos Omega Pharmaceuticals.
Ticos Omega Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 43.47% increase in profit. The company's net worth observed a substantial decline by a decrease of 87.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ticos Omega Pharmaceuticals?
Unlock access to Ticos Omega Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Ticos Laboratories Private LimitedActive 14 years 8 months
Payal Patel and Jaynesh Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ticos Omega Pharmaceuticals?
Unlock and access historical data on people associated with Ticos Omega Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ticos Omega Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ticos Omega Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
